檢索結果 - Andrzej Hellmann

Refine Results
  1. 1
    Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients

    Prevalence of acquired von Willebrand syndrome during essential thrombocythemia: a retrospective analysis of 170 consecutive patients 由 Andrzej Mital, Witold Prejzner, Maria Bieniaszewska, Andrzej Hellmann

    出版 2015
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  2. 2
    The Role of Lipid Metabolism Disorders in the Development of Thyroid Cancer

    The Role of Lipid Metabolism Disorders in the Development of Thyroid Cancer 由 Martyna Łukasiewicz, Agata Zwara, Jacek Kowalski, Adriana Mika, Andrzej Hellmann

    出版 2024
    獲取全文 獲取全文
    Revisão
    加到收藏夾
    Saved in:
  3. 3
    Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation

    Colonization with multidrug-resistant bacteria increases the risk of complications and a fatal outcome after allogeneic hematopoietic cell transplantation 由 Alicja Sadowska‐Klasa, Agnieszka Piekarska, Witold Prejzner, Maria Bieniaszewska, Andrzej Hellmann

    出版 2017
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  4. 4
    Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential

    Promising Therapeutic Strategies for Hematologic Malignancies: Innovations and Potential 由 Jan Jakub Lica, Bhaskar Pradhan, Kawthar Safi, Joanna Jakóbkiewicz‐Banecka, Andrzej Hellmann

    出版 2024
    獲取全文
    Revisão
    加到收藏夾
    Saved in:
  5. 5
    Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream

    Leukemia and risk of recurrent Escherichia coli bacteremia: genotyping implicates E. coli translocation from the colon to the bloodstream 由 A Samet, Anna Śledzińska, Beata Krawczyk, Andrzej Hellmann, Stella Nowicki, Józef Kur, B. Nowicki

    出版 2013
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  6. 6
    A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management

    A randomized comparison of two prophylaxis regimens and a paired comparison of on‐demand and prophylaxis treatments in hemophilia A management 由 Leonard A. Valentino, Vasily Mamonov, Andrzej Hellmann, Doris Quon, Alicja Chybicka, P Schroth, Lisa Patrone, Wing-Yen Wong

    出版 2011
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  7. 7
    Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials

    Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo‐controlled trials 由 James B. Bussel, Donald M. Arnold, Elliot Grossbard, Jiřı́ Mayer, Jacek Treliński, Wojciech Homenda, Andrzej Hellmann, Jerzy Windyga, Liliya Sivcheva, Alhossain A. Khalafallah, Francesco Zaja, Nichola Cooper, Vadim Markovtsov, Hany Zayed, Anne‐Marie Duliège

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  8. 8
    First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial

    First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial 由 Anton Hagenbeek, Ole Gadeberg, Peter Johnson, Lars Møller Pedersen, Jan Walewski, Andrzej Hellmann, Brian K. Link, Tadeusz Robak, Marek Z. Wojtukiewicz, Michael Pfreundschuh, Michael Kneba, Andreas Engert, Pieter Sonneveld, Mimi Folden Flensburg, Jørgen Holm Petersen, Nedjad Losic, John Radford

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  9. 9
    Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia

    Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia 由 Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, Jose A. García‐Marco, Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger

    出版 2016
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  10. 10
    Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial

    Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial 由 Hagop Kantarjian, Ricardo Pasqüini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Hołowiecki, Saengsuree Jootar, Tadeusz Robak, Н Д Хорошко, Tamás Masszi, Aleksander B. Skotnicki, Andrzej Hellmann, Andrey Zaritsky, А К Голенков, Jerald P. Radich, Timothy P. Hughes, Athena Countouriotis, Neil P. Shah

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  11. 11
    Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma 由 Meletios Α. Dimopoulos, Andrew Spencer, Michael Attal, H. Miles Prince, Jean‐Luc Harousseau, Anna Dmoszyńska, Jesús F. San Miguel, Andrzej Hellmann, Thierry Façon, Robin Foà, Alessandro Corso, Zvenyslava Masliak, Marta Olesnyckyj, Zhinuan Yu, John Patin, Jerome B. Zeldis, Robert Knight

    出版 2007
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  12. 12
    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML 由 Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, Andrzej Hellmann, David Taussig, Mar Tormo, Maria Teresa Voso, James D. Cavenagh, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Lewis R. Silverman

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  13. 13
    Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study

    Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group... 由 Jerzy Hołowiecki, Małgorzata Krawczyk‐Kuliś, Sebastian Giebel, Krystyna Jagoda, Beata Stella‐Hołowiecka, Beata Piątkowska‐Jakubas, Monika Paluszewska, Ilona Seferyńska, Krzysztof Lewandowski, Marek Kiełbiński, Anna Czyż, Agnieszka Balana‐Nowak, Maria Król, Aleksander B. Skotnicki, W Wiktor-Jędrzejczak, Krzysztof Warzocha, Andrzej Lange, Andrzej Hellmann

    出版 2008
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  14. 14
    Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Polish Adult Leukemia Group (PALG-CLL3 Study)

    Comparison of Cladribine Plus Cyclophosphamide With Fludarabine Plus Cyclophosphamide As First-Line Therapy for Chronic Lymphocytic Leukemia: A Phase III Randomized Study by the Po... 由 Tadeusz Robak, Krzysztof Jamroziak, Joanna Góra‐Tybor, Beata Stella‐Hołowiecka, L Konopka, B. Ceglarek, Krzysztof Warzocha, Ilona Seferyńska, Jarosław Piszcz, Małgorzata Całbecka, Aleksandra Kostyra, Jadwiga Dwilewicz‐Trojaczek, Anna Dmoszyńska, Krystyna Zawilska, Andrzej Hellmann, A Zduńczyk, S Potoczek, Magdalena Piotrowska, Krzysztof Lewandowski, Jerzy Z. Błoński

    出版 2010
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  15. 15
    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome 由 Jorge E. Cortés, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, P. Desjardins, Oliver G. Ottmann, Weidong Wendy, M. Naveed Shaik, A. Douglas Laird, Mirjana Zeremski, Ashleigh O’Connell, Geoffrey Chan, Michael Heuser

    出版 2018
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  16. 16
    Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

    Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes 由 Peter Valent, Amy D. Klion, Hans‐Peter Horny, Florence Roufosse, Jason Gotlib, Peter F. Weller, Andrzej Hellmann, Georgia Metzgeroth, Kristin M. Leiferman, Michel Arock, Joseph H. Butterfield, Wolfgang R. Sperr, Karl Sotlar, Peter Vandenberghe, Torsten Haferlach, Hans‐Uwe Simon, Andreas Reiter, Gerald J. Gleich

    出版 2012
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  17. 17
    Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

    Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia 由 William G. Wierda, Thomas J. Kipps, Jiřı́ Mayer, Stephan Stilgenbauer, Cathy Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trněný, Martin J.S. Dyer, Swaminathan P. Iyer, Magdalena Piotrowska, Tomáš Kozák, Geoffrey Chan, Randy Davis, Nedjad Losic, Joris Wilms, Charlotte Russell, Anders Österborg

    出版 2010
    獲取全文
    Artigo
    加到收藏夾
    Saved in:
  18. 18
    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial

    Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial 由 Jerald P. Radich, Andreas Hochhaus, Tamás Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez‐Casares, Valentín García‐Gutiérrez, Eibhlin Conneally, Philipp D. le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saußele, Francis J. Giles, David M. Ross, Paola Aimone, Sai Li, Ksenia Titorenko, Giuseppe Saglio

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  19. 19
    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes

    A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes 由 Amer M. Zeidan, Isaac W. Boss, C.L. Beach, Wilbert B. Copeland, Ethan Thompson, Brian A. Fox, Vanessa Hasle, K. OGASAWARA, James D. Cavenagh, Lewis R. Silverman, Maria Teresa Voso, Andrzej Hellmann, Mar Tormo, Tim O’Connor, Alessandro Previtali, Shelonitda Rose, Guillermo Garcia‐Manero

    出版 2021
    獲取全文 獲取全文
    Artigo
    加到收藏夾
    Saved in:
  20. 20
    Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up

    Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up... 由 Jorge E. Cortés, Hagop M. Kantarjian, Delphine Réa, Meir Wetzler, Jeffrey H. Lipton, Luke P. Akard, H. Jean Khoury, Mauricette Michallet, Agnès Guerci‐Bresler, Charles Chuah, Andrzej Hellmann, Raghunadharao Digumarti, Purvish M. Parikh, Laurence Legros, Krzysztof Warzocha, Michele Baccarani, Elizabeth Li, Mihaela Munteanu, Franck E. Nicolini

    出版 2015
    獲取全文
    Artigo
    加到收藏夾
    Saved in:

檢索工具: